DURECT (NASDAQ:DRRX – Get Free Report) is expected to post its quarterly earnings results before the market opens on Wednesday, March 26th. Analysts expect DURECT to post earnings of ($0.02) per share and revenue of $6.91 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.
DURECT Stock Up 6.1 %
DRRX opened at $0.85 on Monday. DURECT has a twelve month low of $0.70 and a twelve month high of $1.88. The stock has a market capitalization of $26.35 million, a price-to-earnings ratio of -1.39 and a beta of 0.91. The company has a 50-day simple moving average of $0.80 and a 200 day simple moving average of $1.02.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on shares of DURECT in a research note on Wednesday, March 19th. They issued a “sell” rating on the stock.
About DURECT
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
Read More
- Five stocks we like better than DURECT
- 3 REITs to Buy and Hold for the Long Term
- AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- 3 ETFs to Ride the VIX Surge During Market Volatility
- How to trade using analyst ratings
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.
